Avacopan

Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.

Product Specifications

CAS Number

[1346623-17-3]

Product Name Alternative

CCX168

UNSPSC

12352005

Hazard Statement

H302, H410

Target

Complement System

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Avacopan.html

Purity

99.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H]1[C@H](C2=CC=C(NC3CCCC3)C=C2)N(C(C4=C(C)C=CC=C4F)=O)CCC1)NC5=CC=C(C)C(C(F)(F)F)=C5

Molecular Formula

C33H35F4N3O2

Molecular Weight

581.64

Precautions

H302, H410

References & Citations

[1]Bekker P, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016 Oct 21;11 (10) :e0164646.|[2]Xiao H, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014 Feb;25 (2) :225-31.